Mednet Logo

How do you approach patients with SMARCB1 deficient sinonasal carcinoma for immunotherapy?

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Answered on

Sinonasal cancers that are SMARCB1-deficient are rare. They tend to be more aggressive, present in more advanced stages, and tend to be associated with non-keratinizing histology. Despite this, there are no guidelines for a differential approach for these tumors and they are treated in a similar fas...

Join for free or sign in to see the full answer